Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2) [Phase 3]

View source ↗

Summary

The document reports the completed Phase 3 UNITI-2 trial assessing ustekinumab induction therapy for moderately to severely active Crohn's disease, with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Stelara (ustekinumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Crohn's Disease, Inflammatory Bowel Disease | Phase 3 | Status: COMPLETED | Results posted: 2017-01-06